DISCLOSURES: The American Heart Association, American Cancer Society, and American Urological Association make every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the writing panel. Specifically, all members of the writing group are required to complete and submit a Disclosure Questionnaire showing all such relationships that may be perceived as real or potential conflicts of interest.
Article first published online: 3 FEB 2010
Copyright © 2010 American Cancer Society, Inc.
CA: A Cancer Journal for Clinicians
Volume 60, Issue 3, pages 194–201, May/June 2010
How to Cite
Levine, G. N., D'Amico, A. V., Berger, P., Clark, P. E., Eckel, R. H., Keating, N. L., Milani, R. V., Sagalowsky, A. I., Smith, M. R. and Zakai, N. (2010), Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular Risk: A Science Advisory From the American Heart Association, American Cancer Society, and American Urological Association: Endorsed by the American Society for Radiation Oncology. CA: A Cancer Journal for Clinicians, 60: 194–201. doi: 10.3322/caac.20061
The reviewers had no conflicts of interest to disclose.
These disclosures represent the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be “significant” when 1) the person receives $10,000 or more during any 12-month period or 5% or more of the person's gross income, or 2) the person owns 5% or more of the voting stock or share of the entity or owns $10,000 or more of the fair market value of the entity. A relationship is considered to be “modest” when it is less than “significant” under the preceding definition. *Modest. †Significant.
This advisory was approved by the American Heart Association Science Advisory and Coordinating Committee on September 18, 2009, by the American Cancer Society on September 4, 2009, and by the American Urological Association on September 4, 2009.
This article has been copublished in Circulation. 2010;121:(In Press).
Expert peer review of AHA Scientific Statements is conducted at the AHA National Center. For more on AHA statements and guidelines development, visit http://www.americanheart.org/presenter.jhtml?identifier=3023366.
This document is available on the World Wide Web sites of the American Heart Association (http://my.americanheart.org), American Cancer Society (http://cajournal.org and http://cacancerjournal.org), and American Urological Association (http://www.auanet.org). A copy of the document is available at http://www.americanheart.org/presenter.jhtml?identifier=3003999 by selecting either the “topic list” link or the “chronological list” link (No. KB-0015).
The writing group made the following disclosures:
Peter Berger is a consultant to Accumetrics,* Eli Lilly & Co/Daiichi Sankyo,* PlaCor,* and The Medicines Company.*
Robert H. Eckel is on the speakers' bureau of Innovia (Sanofi-Aventis-sponsored event), and has a research grant and is a consultant to Sanofi-Aventis.*
Arthur I. Sagalowsky is a consultant to Bioniche/Parexel,* and is on the data monitoring committee for the Bioniche* bladder cancer trial
Matthew R. Smith receives research support from the Lance Armstrong Foundation† and the Prostate Cancer Foundation† and is a consultant to GTX†
- Issue published online: 5 MAY 2010
- Article first published online: 3 FEB 2010